Literature DB >> 2811596

The role of the 5-HT2 receptor in the regulation of sexual performance of male rats.

M M Foreman1, J L Hall, R L Love.   

Abstract

The present studies have attempted to evaluate the role of 5-HT2 receptors in the regulation of sexual behavior of male rats by determining the effects of 5-HT2 receptor antagonists, pirenperone, LY53857 and LY281067, and a 5-HT2 receptor agonist, DOI. The administration of 1 mg/kg s.c. pirenperone produced a total suppression of ejaculatory response and lower doses had no effect. However, the administration 0.1 mg/kg s.c. of either LY53857 or LY281067 restored ejaculatory capacity to rats that were unable to ejaculate and produced significant decreases in ejaculatory latency in rats with full sexual capacity. Although all of these agents are 5-HT2 antagonists, LY53857 and LY281067 lack the additional monoaminergic activity of pirenperone. Since the effects of pirenperone were opposite from the effects of the selective 5-HT2 antagonists, the suppressive effects of this agent were probably related to its other monoaminergic activity e.g. alpha 1 antagonist activity. This proposal was supported by the observation that the administration of prazosin, an alpha 1 antagonist, significantly increased ejaculatory latency and suppressed the stimulatory effects of LY53857. In contrast to the stimulatory effects of the selective 5-HT2 antagonists, the administration of DOI, resulted in a suppression of sexual performance, which was blocked by pretreatment with LY53857.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2811596     DOI: 10.1016/0024-3205(89)90128-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  19 in total

Review 1.  Advances in understanding and treating premature ejaculation.

Authors:  Theodore R Saitz; Ege Can Serefoglu
Journal:  Nat Rev Urol       Date:  2015-10-27       Impact factor: 14.432

Review 2.  Ejaculatory disorders: epidemiology and current approaches to definition, classification and subtyping.

Authors:  Emmanuele A Jannini; Andrea Lenzi
Journal:  World J Urol       Date:  2005-05-18       Impact factor: 4.226

Review 3.  Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment.

Authors:  Marcel D Waldinger
Journal:  World J Urol       Date:  2005-06-02       Impact factor: 4.226

4.  Activation of lumbosacral 5-HT2C receptors induces bursts of rhythmic activity in sympathetic nerves to the vas deferens in male rats.

Authors:  Stuart A Stafford; Kim Tang; John H Coote
Journal:  Br J Pharmacol       Date:  2006-06-26       Impact factor: 8.739

5.  Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.

Authors:  Trynke R de Jong; Tommy Pattij; Jan G Veening; Marcel D Waldinger; Alexander R Cools; Berend Olivier
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

6.  A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes.

Authors:  L Marson; K E McKenna
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

7.  Role of nitric oxide in penile erection and yawning induced by 5-HT1c receptor agonists in male rats.

Authors:  M R Melis; R Stancampiano; A Argiolas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

8.  Serotonergic influences on male sexual behavior of rhesus monkeys: effects of serotonin agonists.

Authors:  S M Pomerantz; B C Hepner; J M Wertz
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Extracellular serotonin in the lateral hypothalamic area is increased during the postejaculatory interval and impairs copulation in male rats.

Authors:  D S Lorrain; L Matuszewich; R D Friedman; E M Hull
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

Review 10.  Disorders of ejaculation.

Authors:  E A Jannini; C Simonelli; A Lenzi
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.